Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Hematology

The Root Cause: Genetics and Autoantibodies in aHUS

At a Glance

Atypical hemolytic uremic syndrome (aHUS) is driven by an overactive alternative complement pathway that attacks blood vessels. It is typically caused by a combination of a genetic mutation or autoantibody (like anti-CFH) and an environmental trigger, such as an infection, pregnancy, or surgery.

At its core, atypical Hemolytic Uremic Syndrome (aHUS) is a disease of the immune system. Specifically, it involves the alternative complement pathway, a part of your immune system that is always “on” at a low level, acting like a security guard ready to attack bacteria and viruses [1][2]. In aHUS, this security guard loses the ability to recognize your own cells and begins attacking the lining of your blood vessels (the endothelium) [1][3].

The “Stuck Switch”: Why Complement Doesn’t Turn Off

In a healthy person, the body produces “brakes” (regulatory proteins) that prevent the complement system from attacking its own cells. In aHUS, these brakes are either missing or broken [4][2]. This leads to unbridled complement activity, causing the tiny blood clots and organ damage seen in a flare [1][5].

The Genetics of aHUS

About 50% to 60% of people with aHUS have a known genetic mutation that affects these complement “brakes” [6][7]. The most common mutations include:

  • CFH (Factor H): This is the most frequent mutation. Factor H is the primary “brake” in the blood. Mutations here are often associated with a higher risk of kidney failure and a higher chance of the disease returning after a transplant [8][9].
  • CFI (Factor I): This protein helps break down active complement components. Mutations can lead to severe disease and progression to kidney failure [10][11].
  • CD46 (MCP): Unlike Factor H, this protein is attached to the surface of your cells. People with CD46 mutations often have many relapses, but their kidneys often recover better than those with other mutations [12].
  • C3 and CFB: These are the “gas pedals” of the system. Mutations here make the system too powerful, leading to constant activation [13][7].

It is important to know that up to 40-50% of patients will have a “negative” genetic test, meaning science hasn’t yet identified the specific mutation causing their disease [7][14]. A negative test does not mean you don’t have aHUS.

Family Genetic Testing: When a genetic mutation is found, finding out your children or siblings might carry it can cause immense guilt and anxiety. Testing usually involves a simple blood or saliva test. Talk to a genetic counselor about whether to test children immediately or wait until they are older or show symptoms [15]. Just carrying a mutation does not guarantee they will ever get sick.

Acquired aHUS: Anti-CFH Antibodies

Sometimes, the problem isn’t a mutation you were born with, but an autoantibody your body has created. Anti-Factor H (anti-CFH) antibodies are proteins that stick to your Factor H and stop it from working [16][17].

  • This form is more common in children and is often linked to a specific missing piece of DNA (CFHR1/CFHR3 deletion) [18][19].
  • Knowing if these antibodies are present is critical because doctors may add immunosuppressive therapy (like steroids or other drugs) to the treatment plan to stop the body from making the antibodies [20][21].

The Two-Hit Hypothesis: Navigating Triggers

Most people with an aHUS mutation are born with it, but they don’t have symptoms every day. This is explained by the Two-Hit Hypothesis [1][22].

  1. Hit 1 (The Genetics): You are born with a “weakness” or mutation in your complement system.
  2. Hit 2 (The Trigger): An environmental stressor—like a common cold, the flu, pregnancy, surgery, or even a vaccination—causes the complement system to rev up [23][24]. Because of Hit 1, the system can’t turn itself back off, leading to a flare [25].

Living With Triggers: Hearing that pregnancy or surgery can trigger a flare can be terrifying. This doesn’t mean you can never have children or get your wisdom teeth out. It just means you must plan these events carefully with your hematologist or nephrologist, who may use medications (like restarting complement inhibitors temporarily) to protect your kidneys during those high-stress times [26][23].

The Vaccine Paradox: You might wonder: If vaccinations can trigger a flare, how can I safely get the mandatory meningitis vaccines required for aHUS treatment? The answer is that once you are protected by the C5 inhibitor medication, it acts as a shield. The medication prevents the vaccine from triggering a full-blown flare [27]. In many cases, doctors will start the inhibitor and use prophylactic antibiotics to protect you while the vaccine takes effect [28].

Common questions in this guide

What causes atypical hemolytic uremic syndrome (aHUS)?
aHUS is caused by an overactive alternative complement pathway, a part of the immune system. In aHUS, this system loses the ability to recognize your own cells and mistakenly attacks the lining of your blood vessels, leading to clots and organ damage.
What does it mean if my aHUS genetic test is negative?
Up to half of patients with aHUS will have a negative genetic test, meaning science hasn't yet identified the specific mutation causing their disease. A negative test does not mean you do not have aHUS, and your doctor will still manage your treatment based on your diagnosis.
What are anti-CFH antibodies in aHUS?
Anti-Factor H (anti-CFH) antibodies are proteins your body creates that stick to Factor H, preventing it from acting as a "brake" on your immune system. This form of aHUS is more common in children and may require immunosuppressive therapy to stop the body from making these antibodies.
Can pregnancy or surgery trigger an aHUS flare?
Yes, environmental stressors like pregnancy, surgery, or infections can trigger a flare in people who have an underlying genetic weakness in their complement system. However, with careful planning and management by your hematologist or nephrologist, these events can often be navigated safely.
Are vaccines safe if I have aHUS?
While vaccinations can sometimes act as a trigger, patients on C5 inhibitor medications are protected. The medication acts as a shield, preventing the vaccine from triggering a full-blown flare while allowing you to safely receive mandatory vaccines like those for meningitis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific genetic mutation, if any, was found in my (or my child's) complement panel?
  2. 2.Was I tested for anti-Factor H (anti-CFH) antibodies, and if so, what was the level?
  3. 3.Based on my genetic results, what is my estimated risk of a future relapse?
  4. 4.How does my genetic profile affect the possibility or success of a future kidney transplant?
  5. 5.If no mutation was found, does that change my diagnosis or how my treatment is managed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    Hypertensive Crisis and Refractory Hypertension Caused by Atypical Hemolytic Uremic Syndrome and Effect of Eculizumab.

    Chen FY, Chen CH, Lin CC

    Acta Cardiologica Sinica 2018; (34(5)):446-449 doi:10.6515/ACS.201809_34(5).20180326D.

    PMID: 30271097
  2. 2

    An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

    Campistol JM, Arias M, Ariceta G, et al.

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2015; (35(5)):421-47.

    PMID: 26456110
  3. 3

    Atypical Hemolytic Uremic Syndrome: A Brief Review.

    Zhang K, Lu Y, Harley KT, Tran MH

    Hematology reports 2017; (9(2)):7053 doi:10.4081/hr.2017.7053.

    PMID: 28626544
  4. 4

    [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].

    Kistler AD

    Praxis 2016; (105(7)):389-96 doi:10.1024/1661-8157/a002308.

    PMID: 27005733
  5. 5

    Diagnosis of Bone Marrow Necrosis following Severe Vaso-Occlusive Crisis in Patient with Compound Heterozygous Sickle Cell Disease.

    Marco DN, Cid J, Garrote M, et al.

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2023; (50(4)):360-364 doi:10.1159/000529500.

    PMID: 37767282
  6. 6

    ATYPICAL HEMOLYTIC UREMIC SYNDROME IN AN ADULT SUCCESSFULLY TREATED WITH ECULIZUMAB.

    Chaudoir C, Ong MG, Gu X, et al.

    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 2016; (168(1)):12-5.

    PMID: 26986861
  7. 7

    Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome.

    Yun JW, Oh J, Lee KO, et al.

    Thrombosis research 2020; (194()):45-53 doi:10.1016/j.thromres.2020.06.016.

    PMID: 33213850
  8. 8

    Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.

    Martín Merinero H, Zhang Y, Arjona E, et al.

    Blood 2021; (138(22)):2185-2201 doi:10.1182/blood.2021012037.

    PMID: 34189567
  9. 9

    Genetics and outcome of atypical hemolytic-uremic syndrome in Turkish children: a retrospective study between 2010 and 2017, a single-center experience.

    Conkar S, Mir S, Berdeli A

    Iranian journal of kidney diseases 2019; (13(5)):316-321.

    PMID: 31705748
  10. 10

    High prevalence of the hotspot complement factor I p.Ile357Met pathogenic variant in Tunisian atypical hemolytic uremic syndrome patients: report of three new cases and review of the literature.

    Tajouri A, Ayadi I, BenBrahim R, et al.

    Frontiers in immunology 2025; (16()):1623432 doi:10.3389/fimmu.2025.1623432.

    PMID: 40895567
  11. 11

    A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report.

    Wei X, Li J, Zhan X, et al.

    Journal of medical case reports 2022; (16(1)):101 doi:10.1186/s13256-022-03312-y.

    PMID: 35241161
  12. 12

    Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome.

    Khandelwal P, Birla S, Bhatia D, et al.

    Clinical kidney journal 2018; (11(2)):198-203 doi:10.1093/ckj/sfx078.

    PMID: 29644059
  13. 13

    Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome.

    Fujisawa M, Kato H, Yoshida Y, et al.

    Clinical and experimental nephrology 2018; (22(5)):1088-1099 doi:10.1007/s10157-018-1549-3.

    PMID: 29511899
  14. 14

    Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.

    Fakhouri F, Fila M, Hummel A, et al.

    Blood 2021; (137(18)):2438-2449 doi:10.1182/blood.2020009280.

    PMID: 33270832
  15. 15

    Case report - atypical hemolytic uremic syndrome triggered by influenza B.

    Kobbe R, Schild R, Christner M, et al.

    BMC nephrology 2017; (18(1)):96 doi:10.1186/s12882-017-0512-y.

    PMID: 28320387
  16. 16

    The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.

    Fujisawa M, Yasumoto A, Kato H, et al.

    British journal of haematology 2020; (189(1)):182-186 doi:10.1111/bjh.16297.

    PMID: 31879952
  17. 17

    The Factor H protein family: The switchers of the complement alternative pathway.

    Lucientes-Continente L, Márquez-Tirado B, Goicoechea de Jorge E

    Immunological reviews 2023; (313(1)):25-45 doi:10.1111/imr.13166.

    PMID: 36382387
  18. 18

    Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children.

    Štolbová Š, Bezdíčka M, Seeman T, et al.

    European journal of pediatrics 2020; (179(11)):1739-1750 doi:10.1007/s00431-020-03666-9.

    PMID: 32424742
  19. 19

    Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study.

    Wu D, Chen J, Ling C, et al.

    Nephron 2021; (145(4)):415-427 doi:10.1159/000513009.

    PMID: 33873197
  20. 20

    Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.

    Khandelwal P, Thomas CC, Rathi BS, et al.

    Journal of clinical apheresis 2019; (34(5)):555-562 doi:10.1002/jca.21711.

    PMID: 31173399
  21. 21

    Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases.

    Li Q, Kong X, Tian M, et al.

    Renal failure 2022; (44(1)):1061-1069 doi:10.1080/0886022X.2022.2089167.

    PMID: 35730179
  22. 22

    Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge.

    Jiménez Mayor E, De La Flor JC, Rocha Rodrigues A, et al.

    Diseases (Basel, Switzerland) 2025; (13(5)) doi:10.3390/diseases13050153.

    PMID: 40422585
  23. 23

    C3 p.Asp1115Asn Variant-associated Atypical Hemolytic Uremic Syndrome with Spontaneous Remission Triggered by Influenza and COVID-19.

    Fujino Y, Hanada H, Takata T, et al.

    Internal medicine (Tokyo, Japan) 2026; (65(8)):1152-1157 doi:10.2169/internalmedicine.6036-25.

    PMID: 40930830
  24. 24

    Atypical Hemolytic Uremic Syndrome: A Case Report.

    Mohammed SK, Mubarik A, Nadeem B, et al.

    Cureus 2019; (11(5)):e4634 doi:10.7759/cureus.4634.

    PMID: 31312560
  25. 25

    Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.

    Kozlovskaya NL, Korotchaeva YV, Bobrova LA

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2019; (32(17)):2853-2859 doi:10.1080/14767058.2018.1450381.

    PMID: 29606012
  26. 26

    Case series: coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: two case reports.

    Kurian CJ, French Z, Kukulich P, et al.

    Journal of medical case reports 2021; (15(1)):587 doi:10.1186/s13256-021-03144-2.

    PMID: 34903272
  27. 27

    Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

    Mallenahalli Neeekantappa V, Kamath A, Bharathi Rajaduraivelpandian P

    Medicina (Kaunas, Lithuania) 2024; (60(3)) doi:10.3390/medicina60030379.

    PMID: 38541105
  28. 28

    [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

    Guo DD, Xiao YX, Wang WR, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(11)):1408-1413 doi:10.7499/j.issn.1008-8830.2503084.

    PMID: 41250542

This page provides educational information about the genetics and root causes of aHUS. It is not a substitute for professional medical advice, diagnosis, or genetic counseling from your hematologist or nephrologist.

Get notified when new evidence is published on Atypical hemolytic uremic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.